The pharmaceutical industry manufactures products of the highest importance to society. Keeping the cost of the production of medicines at low levels is very important to ensure better accessibility to medicines, especially if we think of the less wealthy countries of the planet. Among the production steps that need to be carefully monitored and optimized, the final packaging phase is sometimes considered less important. This is a mistake, because, being the last stage of production, it can negatively affect all other upstream phases. The aim of this work is to evaluate whether the throughput and work in process diagrams can be useful for the rapid and effective control of the line activity. The result was positive, given that, with the help of a case study, we could identify four patterns corresponding to the same number of typical operating conditions of the line, either regular or altered. After identifying the typical pattern of the line studied, the use of such diagrams can be employed either in real-time or retrospectively for an accurate analysis of the behaviour of the production line.
Introduction
The pharmaceutical industry is one of the world's most important production sectors. First of all, its importance is related to the category of such products: drugs, in fact, are essential to attend, to prevent and to alleviate the effects of the bulk of the syndromes that can damage people, thus contributing to keeping good health.
Nowadays, drugs are widespread in most industrialized countries, though they are not yet equally available in developing ones.
The unavailability of drugs for the poorest has many causes: the unavailability of suitable human, technical and financial resources; the low purchasing power of the Third World; the running out of production of nonfruitful drugs, their use only for the diseases of developing countries [1], etc.
This situation occurs even though the World Health Organization (WHO), which is the association dealing with international public health, has defined a list of essential medicines that should be available everyone around the world. The last updated list was drawn up around one year ago, in April 2013 [2] .
The manufacture of products with high social impact is only one of two sides of the coin of pharmaceutical firms. On the other hand, significantly, they are firms, with all the features related to a productive background and, notably, the necessity to have a profit margin.
According to the Boston Consulting Group [3] , the pharmaceutical industry is one of the world's most profitable businesses, most obviously because its products have a high added value per mass unit [4] . We can consider the example of the bio-pharmaceutical firm Pharmacyclics [3]: during the period from 2008 to 2012, its average total shareholder return was about 109%.
The attainment of a high profit in this industry is, however, quite difficult to achieve and maintain over time. For this reason, it is very important to apply specific strategies to have a strong, competitive advantage.
The reasons for this complexity are related to the specific structure of the pharmaceutical industry, comprising patents, huge investments, and long lead times and product pipelines. Drugs production, in fact, has several different phases, the first of which, research [5] , entails huge financial, human and time investments. Furthermore, only a small percentage of the new substances identified during the research phase as a final point becomes a real drug.
After a new drug's discovery and development, we have the production phase. Production control is extremely important, since it affects the profitability of the entire process. This is why a great deal of attention must be given to effectiveness and efficiency, using theoretical approaches or more complex simulation strategies.
After manufacturing activities, the packaging phase takes place. Packaging activity represents a direct link between production and sales [6] , essential for the commercialization of products to final consumers. Even though it is the last activity of the production chain, packaging elements might be considered during the first phases of the manufacturing process and development. In fact, it is an essential and central part in the retail and commercialization of products, and a key point in the marketing mix definition. Good packaging management, moreover, requires a deep knowledge of operations management and operations research [7] . Packaging lines need to be deeply analysed as well as other production systems, along with complex approaches like simulation [8] .
The packaging of a product is strictly related to its appearance for potential customers: this element, in fact, can be an important factor in the choice of one product compared to its competitors.
In the pharmaceutical sector, however, the appearance of a product is less important than in the many sectors. The majority of drugs, in fact, are prescribed by doctors based on their active principles. Over-the-counter drugs, on the other hand, are chosen by patients personally in relation to usual utilization, to the producer pharmaceutical firm, to possible allergies and also -perhaps -to their packaging.
The package provides protection for products [9] , which is essential to retailing, carriage and selling activities. This function is crucial for fragile products, for example, drugs requiring a specific temperature for conservation and transportation.
For pharmaceutical products' commercialization, the package of the final products can perform several functions [10] , such as:
• Containment: this is the main function required of the drug package; it could be appropriate to drug features, manufacturing and transportation necessities.
• Protection: the package must protect medicines from the external environment and all possible contamination factors [11] , like light, dust and biological substances, etc. • Preservation and information: looking at the package, consumers must be able to obtain all the main information about the product they want to buy. • Identification: the package must allow the customer to identify and distinguish a product from any competitors. • Convenience: for some kinds of medicines, it is essential that the product should have a package of suitable size (the size of eye drops, for example, is designed for the need to use the product within a few days of opening the package).
The material used is another important element in packaging activities, since it must be suitable to contain substances for inhaling, eating and injections, etc. In recent years, the way in which drugs are used has changed a lot, in favour of inhaling and transdermal giving. These have caused significant improvement in packaging activities: the generation of solutions to the customer's specification is now ever more widespread [10] .
In the pharmaceutical sector, there are several kinds of packages that are chosen according to aspects such as the type of drug (pills, cream, inhaling drugs, etc.), the kind of patient (children, adults, old men, etc.) and the reference market (who administers drugs, whether a doctor or the patient) [10] . The blister pack is the most common package type for solid drugs. Its use is widespread in Europe, while it is also diffusing gradually in the USA [12] (to the detriment of glass bottles). The choice of blister is related to several aspects, and first of all to the certainty of having an intact product, from manufacture to final consumer: to sabotage a blister, in fact, breaking is essential. Moreover, the contamination of an undamaged blister is rather dubious [12] . During packaging and retailing, damage to glass bottles is avoided. There are advantages also for consumers, which can better control the advised dosage in a portable package.
From the above, it stands to reason that each phase of a new drug manufacturing process -from research to the packaging phase -is essential to achieving an inside track on the competition.
Considering the difficulty to achieve and maintain high profit margins in the pharmaceutical industry (because of the specific features of products and markets), it is essential to optimize each phase of the supply chain (SC) [13] . [15] were the first to deal with this subject [13] , presenting an optimization model about research phase problems, capacity planning and investment strategies. Papageorgiou et al. [16] improved the model with additional information about the manufacturing process and the firm's structure. Supply chain optimization models for the pharmaceutical industry have also been used for the identification of the optimal outsourcing level [17] to maximize profit.
Supply chain optimization in a pharmaceutical firm requires both the careful design of its activities and the continuous monitoring of them. Manufacturing and logistic phases, for example, are critical in a SC, and so they are often supervised. Layout design [18] , productivity improvement [19] , effectiveness and efficiency are some of the most important parameters in promptly identifying critical situations and operating in order to eliminate them. The a posteriori analysis of manufacturing and retail process data is also useful to planning some improvement actions.
The possibility of controlling the operating phases of a multi-stage manufacturing process is essential in order to describe the processes and to identify all the undesirable situations. Production control is an optimization problem concerning the definition of when, and how much, to produce [20] . It has two aims, namely customer satisfaction (satisfying demands as quickly as possible) and low in-process inventories [21] .
They are usually classified into push-type systems and pull-type systems [22] . Push control systems are based on systems which consider the available information to predict future customer demand. Pull control systems, on the other hand, are based on considering requests for finished parts as a trigger to produce. Pull production control is applied in between stages that form the production system. Each stage contains a manufacturing process (with the work in progress of the stage) and an output buffer (it contains the finished parts of the stage itself) [23] . Therefore there is a material flow from the upstream to the downstream stages which is caused by a flow of demands moving from the downstream to the upstream stages. The release of parts into each stage, in fact, is associated with the arrival of customer demand for final products [21] .
The most well-known pull control systems are the kanban control system (KCS) and the base stock control system (BSCS). The KCS is based on kanban, which is a production authorization card: demand is forwarded upstream from a generic stage (i) to the previous stage (i-1) only when the parts of the stage i itself flow downstream to the next stage (i+1). For this reason, the KCS restricts the maximal level of WIP and finished parts of a stage [24] . The BSCS, on the other hand, does not allow limiting WIP but is very reactive since, when an external demand arrives, it is immediately transmitted to all the stages of the system. The BSCS tries to maintain a target inventory of finished parts, called a 'base stock' [20] .
These production control systems are very interesting but they are not suitable for high productivity production lines, which can be considered to be a single, very complex machine, and for which other appropriate tools are used. Very interestingly, in these cases, are methods of load-oriented manufacturing control, which are designed to limit and balance the WIP at the lowest level possible for the high utilization of work centres and the rapid flow of orders. This methodology, developed since the 1980s [25] [26] , is particularly useful in production environments where the dynamic variation of the quantities involved causes effects which are very complex to manage with traditional static approaches. This paper, in particular, inspects the use of production diagrams -above all the throughput diagram and the buffer level diagram -as a tool to identify production inefficiencies in a pharmaceutical packaging line. The aim of the study is to demonstrate the possibility of detecting causes of loss of performance thanks to simple instruments.
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